Skip to main content
. 2022 Jan 18;66(1):e01584-21. doi: 10.1128/AAC.01584-21

FIG 3.

FIG 3

Ruxolitinib pharmacokinetics/pharmacodynamics. AL, artemether-lumefantrine. (A) Individual subject ruxolitinib plasma concentration-time profiles. Dashed lines indicate times where sampling was sparse and do not reflect the actual drug concentrations. (B) Individual %pSTAT3 inhibition. Horizontal bars indicate geometric means ± the geometric standard deviations.